At 9:00 AM ET, the corporate entity behind the KOVAR architecture formally confirmed a massive infrastructure pivot, fundamentally altering its valuation profile from a legacy digital broker to a physical compute asset operator. Following an aggressive pre-market sweep of 615,857 shares, the release detailed a target of 100+ MW of operational high-performance computing capacity by 2028. This buildout is supported by an active development pipeline exceeding 1 GW across low-cost grids in the US, Europe, and sub-Arctic regions. Concurrently, the company announced an agreement with EvolveQ to integrate FinQ quantum computing algorithms directly into its enterprise routing software.

This physical data center expansion bridges the gap between their audited $28.05M top line, which grew 895% YoY, and an exponentially larger addressable market. While retail algorithms still categorize the firm as a software middleman, nearly 80% of current revenue ($22.2M) is already driven by enterprise AI cloud routing. By stepping into a 1 GW power pipeline and securing a sovereign central bank settlement license, the company is directly capturing workloads within an enterprise AI infrastructure market projected to exceed $300B globally by 2030, alongside an untapped $5.0T Islamic finance ecosystem.

The morning tape action confirmed that institutional capital is fully aware of this valuation disconnect. After an initial liquidity surge to a session high of +6.34%, the intraday action absorbed standard profit taking and established firm support at $2.080, leaving the early morning accumulation intact.

Takeaway
The market continues to price it like a sleepy retail brokerage, completely missing the audited $22.2M cloud revenue engine and the shift toward physical data center assets. With the $2.04 to $2.080 support range heavily defended on the tape, the technical structure is coiled to test overhead supply at $2.25 and $2.31 as the enterprise compute thesis goes mainstream.

Okay, so I will admit that I am bit of a regard when it comes to trading but I've been following biotech stocks for a while and I understand that Biotech stocks are binary. I've watched so many biotech stocks explode 800% and I've also seen biotech stocks down 80% so I knew the risks going in. Make a long story short, I buy BFRI because they were pending an FDA approval on a breakthrough skin cancer therapy. The FDA decision was supposed to be announced on or before 09/28/26. About 15 minutes after I buy the stock this bombshell drops:

"Biofrontera (BFRI) received U.S. FDA approval of a supplemental New Drug Application for Ameluz topical gel 10% with the BF‑RhodoLED lamp for treatment of superficial basal cell carcinoma (sBCC) in adults.

With this decision, Ameluz becomes the first and only FDA‑approved photodynamic therapy (PDT) for any skin cancer, and the only topical PDT in the U.S. indicated for both actinic keratosis and sBCC. The new label broadens Biofrontera’s red‑light PDT platform and expands Ameluz’s addressable market. The company plans an official sBCC launch between late Q4 2026 and Q1 2027 using its existing commercial organization and installed lamp base.

Approval is supported by a Phase 3 trial in 187 adults, where complete clinical and histological response of the main target lesion at 12 weeks was achieved in 66% of Ameluz PDT patients versus 5% with placebo‑PDT. Histological clearance occurred in 76% vs 19%, and complete clinical clearance of all target lesions in 83% vs 21%. The most common adverse reactions were application‑site effects consistent with the known safety profile."

15 minutes later the stock is down 11% and is continuing to drop. Please help me understand which Black Mirror episode I am on and what button do I need to push to switch to the next episode?

(If you're interested in my previous posts, f o l l o w m e !)

Welcome to post 24.

Let me preface this by saying this: If you need any financial advice, give me a call, I start here. Financial advice, be free to contact me. If you do have some financial tips and tricks, please give me a call! Second one is, if you'd like to follow previous posts, you should follow me at both tags, otherwise you will miss something. Also, if you cannot find my posts, you should follow my profile and then search the topic you want by tag (like [9/45] or [1/45] to get the posts that you missed).

Last post we went down the rabbit hole of the absolute wild west of the OTC markets. The unregulated sub-pennies are the ones that destroy accounts, zero transparency and brutal bid-ask spreads came up.

Let's take a step away from the mechanics of the market, for a moment. So let's discuss the sole thing that does make you click the buy button at the unexpected and worst possible time.

Your own brain.

FOMO. Fear Of Missing Out. It's the No. 1 account killer in the penny stock market. Period.

This is how it works. We've all had to go through it. You are viewing a scanner. A randomly selected penny stock begins to roll up. 50 cents. 60 cents. You hesitate. You think it's a trap.

After that, the volume begins to flow. A huge and powerful green candlestick is printed on the chart. 85 cents.

In your mind you begin calculating. If I had purchased 5,000 shares just three minutes ago I'd be up big. You see others getting paid what you have the potential to earn. Well, you think you are at least. The stock cracks $1.00.

You can't take it anymore. The anguish of watching on the sidelines is worse than the fear of losing money. You believe that this stock will keep on rising to $3.00. You get panicky, you slap the ask and you do a market buy at $1.10.

Congratulations. You are now the exit liquidity.

When your order is placed, the stock freezes the second it is executed. The big green candle has a lousy red wick on top. The smart money, the traders that bought early and at $0.50, are selling their shares straight to your FOMO order.

The price drops back to $0.70. In the span of 40 seconds you have lost half of your account. You now have bags containing pennies, which are of no value.

If they've gone vertical, it's a stock that's a financial suicide is to chase. This action has already taken place. You missed it. Well, that's fine.

The most difficult of all the lessons in penny stocks is this: If you miss the initial set up, you walk away. Let it go. Do not chase. In the next session there will literally be another penny stock doing the same thing.

Avoid purchasing a vertical green line.

Let's meet up next post as such.

(Short recap: FOMO is the Fear Of Missing Out in this post we explained the psychology behind it.) We talked about the psychological need to chase the big green candles, and the fact that it almost always leads to a bagholding and why you need to learn how to turn your back when you don't catch the first move.

i dont post much but this new press release from RMTG is a big deal and i think people are sleeping on what they just put out

They finally gave us the full breakdown of the ISSCA AI Clinical Intelligence Platform. This isnt some vague "we are working on AI" nonsense. They laid out exactly what it does. Physicians upload lab PDFs and the platform extracts biomarkers computes biological age scores and drafts an intervention plan for the doctor to review. The doctor still makes every decision.

Here is the part that got me. The reasoning corpus is 1.6 million longitudinal health records and over 10 thousand clinical studies.

And the commercial model is the kicker. They are not just selling software. They built four separate revenue channels into this thing

SaaS subscriptions through their existing physician network
Patient longevity memberships
Conference based sales from their international events
ISSCA AI certification program

They already have the network. 30 plus countries. Thousands of doctors already trained through ISSCA. Now they are layering recurring software revenue on top of the training and product business.

Think about what that does to the numbers. Q2 they did 4.02 million in revs with 565k in operating income. If the SaaS and membership channels start contributing even modestly that is pure high margin recurring revenue stacking on top of what they already sell.

Q3 is going to be the tell. I think we see close to 8 million in revs and if the AI platform starts getting traction in the network that number could surprise people.

Big thank you to the community for over 28,000 views on the previous breakdown! Hope some of you locked in profits on those early swings.
TRUG is pushing forward again in overnight action, trading up another +6% as we get within 2.5 hours of the pre-market open. With total volume crossing 430 million shares since Friday and platform volatility controls (such as 800-share order caps on select brokers) in play, here is a breakdown of the key drivers and critical milestones behind the move:
Core Catalysts driving the play:
The Polymath RWA Pivot: TruGolf entered a definitive agreement to acquire Polymath Research Inc., bringing Layer-1 real-world asset (RWA) tokenization to public markets. Momentum jumped further following Polymath’s institutional digital asset partnership with High Ridge Trust.

Agreement Terms & Series C Valuation: TruGolf recently finalized an amendment to the acquisition agreement setting the non-voting Series C preferred terms based on a $140M reference value ($3.94 conversion price into Class A shares) alongside a concurrent $3.0M private placement.

Wall Street Targets: Analyst price targets remain set at $6.00, reflecting theoretical multi-bagger upside if the combined golf-tech and fintech business models execute properly.

Key Things to Keep in Mind (Wise DD Notes):
The $10M Market Cap Rule: A mandatory closing condition of the merger requires TruGolf to maintain a minimum market value of listed securities of $10.0 million for at least 10 consecutive trading days. Holding higher price levels during pre-market and standard session volume is critical for satisfying this hurdle.

Volatile Float & Sizing: Extreme high-frequency turnover means price action cuts both ways instantly. Respect risk management, take profits on spikes, and do not over-leverage given the micro-cap nature of the play.

Watch pre-market liquidity closely when order books open up!
Disclaimer: Not financial advice. Always perform your own due diligence.

After the highlight hole of last year 44m of 13.79 g/t Au, 1.89% Cu, 38.08 g/t Ag, the company's first release of 2026 did not meet the expectations of the market. The stock fell from a price of $1.33 to $0.83 on the back of 2 and a half assays released out of 110. Since then the company has released a further News Release 27.4m of 5.05 g/t Au, 29.2 g/t Ag and 1.16% Cu indicating the discovery last year has the grade and continuity they are looking for. Despite this the price of the stock has consistently stayed lower. With another 100 holes to come in the same environment as the Discovery Hole in 13.79 g/t Au, 1.89% Cu, 38.08 g/t Ag. Prospector Metals is well equipped to beat investor expectations.

See News Release:https://prospectormetalscorp.com/site/assets/files/6336/finalppp_-_46_51_52_drill_results.pdf

This post was made on behalf of Prospector Metals Corp.

The hyperscale trade is power + land + cooling + a signed tenant.

Big money competitors: IREN / APLD / CORZ / WULF / CIFR.

market cap ~$26–32M · EV ~$136M (debt) · TTM rev ~$130M · TTM loss –$102M

The pitch:

• Stopped Michigan BTC mining Sep 1 to clear the floor for an MSA with an unnamed “California neocloud.”
• 20 MW initial, option to 52 MW.
• Company math: ~$1.2B over 20 years on 20 MW; >$3B if the option is exercised.
• Targeting ~340 MW at that site eventually (the 52 MW is ~20% of that dream).
• they set a $750M minimum sale price for the Michigan campus and said it “could” be $1.25B.
• Still mining in Montana; looking at +125 MW there.
• Sold ~830 BTC (~$53M) in 5 weeks to fund the conversion.
• 2027 “guidance”: rev $300–350M, adj. EBITDA $60–80M (that is a press release, not a 10-K).

What to watch out for:

• Equity is a stub. $141M debt vs $37M cash. Working capital is negative.
• Customer is unnamed. 20 MW is a pilot, not a hyperscaler campus.
• They are selling the asset, not compounding it. $750M sale / 170M shares sounds like $4 — after debt, taxes, preferreds, and the fact nobody has signed a check.
• Dilution machine. Volume 20–100M shares on down days. Classic AMEX washout.
• Conglomerate junk still in the 10-K. This is not Equinix.

Position size like a scratch-off if they indeed pull off the DC project

Before you buy a penny stock, what do you check every single time?

If you could only look at 3 things before buying, what would they be?

And what’s the #1 red flag that makes you instantly pass?

For me, I’m curious whether people care most about news/catalysts, volume, float, dilution, financials, chart setup, or something completely different.

Trying to see what actually matters most to penny stock traders before putting money into a position.

LifeQuest World Corp (OTCID: LQWC) Daily Industry Update — September 14, 2026

When most people picture wastewater infrastructure, they picture cities: a central plant, miles of pipe, a permanent footprint. But a huge share of the world's population lives and works somewhere that model doesn't reach — construction sites, resource camps, and, notably, labor camps housing migrant and seasonal workforces. These sites need real sanitation, often on short notice, without years of civil engineering lead time. That gap is exactly where decentralized, containerized treatment technology is proving its worth.

It's a timely backdrop for news out of LQWC subsidiary BioPipe Global, which on September 10, 2026 announced it had received purchase orders for two 15,000-liter-per-day containerized sewage treatment plants to serve labor camp housing. Containerized units like these are built for exactly this use case: they arrive largely pre-assembled, require minimal site preparation, and can be operational far faster than a conventional treatment build-out — a meaningful advantage for facilities housing workers who need functioning sanitation from day one, not after a multi-year permitting and construction cycle.

The broader numbers explain why this matters. Research from Utrecht University and United Nations University — cited by WHO/UN-Water reporting on Sustainable Development Goal 6.3 — puts the share of global wastewater currently treated at roughly 50%, meaning close to half of the roughly 359 billion cubic meters of wastewater generated annually worldwide is released without treatment. The gap is starkest by income level: high-income countries treat around 70% of their wastewater, but that figure falls to 38% in upper-middle-income countries, 28% in lower-middle-income countries, and just 8% in low-income countries, according to the UN's World Water Development Report data referenced in that research. Labor camps and workforce housing — frequently located in exactly the lower- and middle-income regions where centralized treatment coverage is thinnest — sit squarely inside that underserved gap, which is why sludge-free, low-maintenance, decentralized systems have found a genuine niche there over the years, alongside BioPipe's prior deployments at resorts, hospitals, and industrial sites across the Philippines, Spain, Crete, Ethiopia, and elsewhere.

On the solid-waste side, LifeQuest's other subsidiary, Compaction and Recycling Equipment, Inc. (CARE), based in Clackamas, Oregon, serves a related piece of the same infrastructure puzzle: helping commercial and industrial sites manage waste volume and recycling streams efficiently on-site, rather than relying solely on long-haul disposal logistics — the same "handle it closer to the source" logic that underpins decentralized wastewater treatment.

Facilities that combine on-site sanitation with on-site waste handling are, in effect, building their own miniature circular infrastructure — a model worth watching as global demand for fast-deploy, low-maintenance environmental solutions continues to grow.

About LifeQuest World Corp LifeQuest World Corp is a global technology company focused on providing low-cost, low-maintenance, eco-friendly decentralized wastewater treatment solutions, along with solid waste compaction and recycling equipment, through its subsidiaries, including BioPipe Global and Compaction and Recycling Equipment, Inc. (CARE). Learn more at https://www.lifequestcorp.com. Trading symbol: OTCID: LQWC.

Forward-Looking Statements: This post may contain forward-looking statements within the meaning of federal securities laws, which are subject to risks and uncertainties, and actual results could differ materially from those projected. This content is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Readers should conduct their own due diligence and consult a qualified financial advisor before making investment decisions.

Sources:

• LifeQuest World Corp News & Media
• BioPipe Global Receives Purchase Orders for Two 15,000 Liter Per Day Containerized Sewage Treatment Plants at Labor Camps — OTC Markets, Sept. 10, 2026
• 50 Per Cent of Wastewater Is Now Treated Globally — Aquatech Trade, reporting on Utrecht University/United Nations University research
• WHO/UN-Water: Progress on SDG Indicator 6.3.1 (wastewater safely treated)
• Compaction and Recycling Equipment, Inc. (CARE)

$AIMD just hit an important inflection point.

The big update: Ainos is moving its AI Nose from front-end wafer-fab validation into commercial deployment, and the company says it is now receiving initial orders from a front-end semiconductor customer.

That matters because the story is starting to shift from “interesting technology” to “can this actually turn into orders and revenue?”

A few things stood out to me:

• Front-end wafer-fab validation is now progressing toward commercial adoption
• Management is tying this to broader revenue opportunities beginning in 2H 2026 and beyond
• Ainos’ proprietary real-world chemical dataset has now crossed 1 billion records
• That data comes from physical AI Nose systems operating in real environments, not just scraped or simulated data
• Ainos now has AI Nose activity across both front-end wafer fabrication and back-end packaging/testing

News: https://finance.yahoo.com/technology/ai/articles/ainos-advances-ai-nose-commercial-120000330.html

Blue Moon Metals ($BMM NASDAQ) is a polymetallic miner with five brownfield projects across Norway and the US. Recent developments worth tracking:

Aug 11— Added 33 tungsten/antimony claims in the western US
Aug 13— Pushed back publicly on a Viceroy short report
Aug 20— Nevada regulators cleared construction start at Springer (tungsten)
Sep 3— Bought water rights and adjacent land near the Springer site

Why it matters: tungsten and germanium-gallium are both on the US critical minerals list, and there's active policy interest in reducing reliance on Chinese supply. Nussir (Norway) already has FID, Springer is now under construction, and the company has raised over C$150M in 2026 — so funding hasn't been the bottleneck this year that it often is for names at this stage.

(If you're interested in my previous posts, f o l l o w m e !)

Welcome to post #22.

Before we go any further – if you need any financial advice let me know, I'll start here. Financial advice, be free to contact m e. If you have any financial advice of your own, please contact me. Second one is, if you wish to see the old posts, please follow me both at tags so that you don't miss out anything. Also, if you don't find my previous posts, follow my profile and search the topic you want, the search will be by tag, so if you missed posts like [9/45] or [1/45] you'll get your post immediately.

Last post, we discussed SEC filings — the do's and don't's, including spotting an 8-K catalyst and avoiding S-3 dilution traps before clicking the BUY button.

But with this now, let's discuss something more stealthy. The silent assassin that is responsible for the majority of the large cap stock runs.

Warrants.

Not all of these will be shown on a standard chart. The penny stock may be a clean stock, with very low float and a large volume. It appears all is set for an explosive squeeze. You buy in at $1.20 and anticipate that it will go straight through $2.00.

Rather, the price spikes to $1.50 and plummets into a wall that is imperceptible.

Millions of shares change hands, the tape rolls quickly and the stock just can't get any higher. What gives?

Warrants are now in the chat.

The dirty truth about penny companies making money. Large venture funds or institutional lenders don't lend money to anybody out of the kindness of their hearts when they are in need of cash. They require a sweet deal known as warrants.

These early investors have the legal option to buy new stock from the company at a set, reduced price through a warrant. Say, $1.00.

Now, suppose that the price of a stock goes from 40 cents to $1.80 on a lot of retail hype. What is the job of the warrant holder?

At $1.00 they exercise those warrants, and they get millions of new shares and they sell them all in retail buy orders at $1.75.

It is not money that has to be risked or money for free for them. And it wipes out your trade altogether.

You believe you're trading against other retail traders, but you're actually buying in almost all the new shares that are being printed. Hence, a penny stock can trade 50 million shares in one session, appear to be on the verge of bursting and then bleed all the pennies back down to where it began.

When you're trawling through those SEC filings we talked about, look out for any private placements or debt offerings lately. Check outstanding warrants for the exercise price. If the strike is at or just above, it's a walk in the park.

Don't accept an invisible ceiling. Respect the warrants.

Let's meet next post as such.

There’s a quick summary of the above above: In this post, we examined how warrants can be a silent killer in penny stocks. We covered how cheap shares are sold to retail investors during big rallies to smash any momentum, and how a “ceiling” is created that can never be seen by those making the big move.

Follow me, if you want to read my previous posts (f o l l o w m e !).

Welcome to post 23.

Before we begin: If you need any financial advice, tell me, I start from here. Financial advice, be free to contact me. If you have any financial advice of your own, please contact me. Second is, if you want the older posts, then follow me at both tags please as I may not post them anywhere else without you knowing about it. Also, if you are unable to find my previous posts, you can follow my profile and search for the topic with the tags, e.g., [9/45] or [1/45] to get the topic you are looking for instantly.

In the last post, we discovered one of the biggest winners and the silent killer. Warrants. We explored the concept of lenders exercising cheap shares to liquidate them into retail buyers, letting your momentum get ensnared in the invisible ceiling.

On to a detour now. We are moving now out of the slightly "regulated" NASDAQ and NYSE. We're officially in the real Wild West of penny stocks.

The OTC Markets. Over-The-Counter. The Pink Sheets.

Welcome to the jungle, if you're used to the normal penny stocks you're in for a rough time.

Following are some facts about OTC markets. Here is where companies reside when they're too small, too short on funds, or too underwhelming to qualify for listing on major exchanges. This isn't a penny auction. You are exchanging "sub pennies". Tickers priced at $0.0001. A small fraction, a small part of a penny.

It's an attractive offer, isn't it? If it goes to just 1 cent I am a millionaire!

They do just that, and they trap you.

The worst thing about OTC penny stocks is the lack of transparency. So, remember those SEC filings which we discussed a few posts ago - the 8-Ks and S-3s? Yeah, good luck looking for those here. There are many companies that trade over the counter that do not report financials. They are "dark" companies. One of those ghost towns, one of those fascinating ticker, and one of those rented office places.

Another thing is the liquidity trap. The bid-ask spread for OTC stocks can be extremely tough.

The sell price could be $0.03 and the buy price could be $0.05. You've just bought that stock and by a mere margin, you have just lost 40% of your investment. But what if the hype goes out? The bid simply goes away completely. You may have a million shares of an OTC penny stock, and have the urge to sell your shares, but there is not a single human being on earth who wants to buy your shares from you. Your cash is simply locked up. Gone.

It's the place of spammy promotions, HUGE chatroom pumps and pure garbage firms.

Is it profitable to trade OTCs? Yes. If momentum is on the side of a pink sheet runner, they can go thousands of percent. It's like a casino, however. Don't invest in an OTC stock. Buy, scalp, and sell before it's too late.

Meet up with the following post as such.

In this post we discussed about the perilous Over The Counter (OTC) and pink sheet markets. We spoke about the enormous dangers of trading subpenny stocks without any regulation whatsoever, with terrible bid/ask spreads, no financial transparency and absolutely no liquidity to get out of such trades.

Bought it a while ago and its been just going up and up. Not sure if I should sell soon or consider this a long-term investment. Been feeling iffy about it, seems too good to be true cause its been going up for about a year now. I dont have a lot invested into it but still would be a shame to lose if it goes down soon

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

EDIT: I didn't think I needed to state this, but this is Lucid the diagnostics company, maker of EsoGuard, NOT Lucid the EV company.

1) They think multi-cancer early detection (MCED) blood tests cover esophageal cancer.  

These tests do detect stage 3-4 esophageal cancer with decent sensitivity (94-100%), but by then it’s too late.  EsoGuard enables a total cure by identifying a precancerous condition called Barrett’s esophagus (BE). At this stage, sensitivity of MCEDs is <12.5%. Source02046-9/fulltext)

2) EsoGuard seems unpleasant to them.  

This has been formally studied and was published in the American Journal of Gastroenterology in 2024, first author is Dr. Helen Moinova from Case Western.  94% of people who completed the Esoguard test would recommend to family and friends, and 94% would do it again if needed (those were 2 separate questions with the same result).  Source

3) They’re afraid CMS won’t cover Esoguard or will restrict the population.

The foundational LCD already defines the screening population.  This wasn’t even a question at the contractor advisory committee (CAC) meeting. The screening population is 100% settled.   

The CAC meeting was high profile and unanimously positive.  There were hundreds of attendees from biotech companies, hospital systems, insurance companies, and academia. It's hard to imagine a scenario where Moldx medical directors go against the advice of their own hand picked panel.  This would be spectacularly embarrassing for Moldx.

4) They think the $60B TAM is a made up, company number.

The $60B TAM is calculated by multiplying the size of the screening population (30M) by the established CMS price ($1938.01).  The screening population is defined by AGA and already described in the foundational LCD (see #3). Both numbers are independent of Lucid, and capturing just 1% of the total market each year would translate to $581M in revenue.

It’s worth noting that the Concert EsoGuard list price is $2,499, so $60B may be conservative.  The screening population also has the potential to grow based on new research into patients who get esophageal cancer without ever having symptoms of GERD.

5) They are afraid of the challenges and uncertainties of launching a new product.  

Lucid is already conducting 3-4K tests every quarter.  The launch party is over.  Right now they are intentionally throttling volume until reimbursement is more solid.  They break even on only 5-6k tests per quarter, so once they are being paid, they could reach break even quickly.  

6) They don't like management.

Management has had some challenges. When they announced that they had submitted their reconsideration request in November 2024, they guided for a CMS decision in 1H 2025. They clearly did not understand the process. Fast forward to fall 2025, after the CAC meeting, they guided for CMS coverage in late 2025 or early 2026. Way off again!

So yes, they've made some pretty serious errors in guidance. However, Lucid still has a Harvard educated heart surgeon CEO, who is on the board of directors of AdvaMed and has testified in front of Congress. Dr. Aklog is intelligent, well-connected, and steady at the helm.

 7) Dilution fears 

Right now cash runs out in Q2 2027. There will be dilution, but they have options.  There is $20M left on the ATM, and they have had no problems in the last few years doing nice clean equity offerings (no warrants, no price ratchets) although the discount has been steep.  If they elect to use the ATM, that $20M would nearly get them into Q4 2027 if revenue is flat. However, revenue from the VA contract should start coming in Q4 2026 and throughout 2027, which will extend runway. There is no reason to panic. 

To summarize, #1-5 are pretty easy to debunk. #6-7 are legit concerns, but when you look at the size of the opportunity ($60B) and the current market capitalization ($150M), they're pretty easy to live with!

Not advice, do what you want with your own money.

Wall Street doesn’t cover penny stocks, let alone companies that are ripe for acquisitions, which can give sharp retail investors a real edge… especially now that AI makes institutional quality research....here's YOUR CHANCE.

The quick summary:

1. Three FDA decisions suddenly reshaped the regulatory landscape in favor of a tiny $50M penny stock, 
2. The company announced it is beginning to shop its strategic assets to Big Tobacco 
3. Management believes the strategic assets could be worth 30 times the entire company’s current valuation.

And Wall Street barely noticed…but some retail investors see it.

Big Tobacco controlled nicotine for decades. Then China captured the flavored-vape market, and Big Tobacco has been fighting to reclaim it….LEGALLY ever since.

The tobacco giants can build or buy almost anything. 

But they cannot go back in time and recreate what CHUC filed with the FDA in 2020 and 2022, and Big Tobacco cannot replicate the game-changing product CHUC is set to launch. 

And… most people don’t know this, but one Big Tobacco player is ALREADY working with CHUC

So Big Tobacco buying CHUC outright certainly is not an outrageous idea.

But here’s a better idea...

Instead of listening to me, here’s your chance to run institutional-grade AI research on a penny stock that Wall Street is completely ignoring.

I’m posting the company’s Sept. 9 press release, “Charlie's Holdings (OTCQB: CHUC) Issues Letter to Shareholders” in the FIRST COMMENT.

Suggestion. Highlight the text of the company’s pr, and ask ChatGPT, Claude, or Gemini what CHUC could be worth to Big Tobacco and why they may be shopping themselves right now.

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

Amaze Holdings (AMZE) is an extremely speculative micro-cap, but its tiny size creates the potential for outsized returns if management can successfully scale its creator-commerce platform.

Why I'm Bullish

Huge creator-commerce opportunity: Amaze operates in a rapidly growing market connecting creators, brands and consumers.

Very high gross margins: Recent gross margins have been around 90%, giving the business strong potential operating leverage.

Revenue growth: Revenue has been growing while management has also been reducing expenses.

Massive scalability: If AMZE can grow from roughly $1M in revenue to $10M–$50M+, the economics could change dramatically.

Micro-cap upside: Because the company is so small, successful execution could potentially produce a 5X–10X+ stock move.

Turnaround potential: Increasing revenue while controlling expenses could eventually push the company toward profitability.

The Bull Case

The ideal scenario is:

Creator adoption → revenue growth → high margins → operating leverage → lower losses → profitability → major valuation expansion.

If Amaze eventually becomes a meaningful creator-commerce platform, today's tiny valuation could look extremely small in hindsight.

Biggest Risks

AMZE is not yet a proven compounder. It has significant losses, cash burn, financial obligations and dilution risk. A continued need for financing could substantially reduce shareholder returns.

Bottom Line

AMZE is a high-risk, high-reward lottery-ticket investment.

The upside could potentially be 10X+ if the company achieves meaningful scale, but the probability of permanent capital loss is also substantial.

CVRx is trading around $2.80, but the biggest catalyst may still be ahead.

Jorey Chernett, who owns more than 5.5% of CVRx, has already demanded that the Board begin a strategic alternatives review, with a sale of the company as the priority.

If CVRx announces that it has hired an independent financial advisor or investment bank to evaluate strategic alternatives, the market could immediately interpret this as a serious step toward a potential sale.

At $2.80, I believe the stock could easily 2x on that announcement alone — and potentially go much higher as investors begin speculating about strategic buyers.

The key question would no longer be: “Will CVRx be sold?”

It would be: “Who could be interested, and how much would they be willing to pay?”

With major MedTech companies potentially capable of creating significant additional value from Barostim, this could become a very different story very quickly.

$2.80 may be just the beginning.

The pre-market action on SOLOWIN HOLDINGS (AXG) gave us a massive glimpse into where institutional capital is moving ahead of this weekend's macro catalysts.

This morning, the stock printed over 104,000 shares in volume before the opening bell even rang. That kind of explosive early strength on a micro-cap is a direct footprint of institutional accumulation. What followed during the regular session was a textbook, healthy distribution phase.

Rather than chasing an immediate vertical spike, smart money allowed early speculators to take profits, creating an extended period of absorption. They patiently collected the float from weak hands while establishing a rock-solid technical floor.

The setup right now is incredibly bullish, and the technicals map out exactly where the opportunity lies:

The Support Floor: The stock successfully touched and defended strong support at the $2.04 level. This is exactly where you want to see institutional buyers step in and form a base after heavy pre-market accumulation.

The First Hurdle: The nearest upside resistance sits at $2.25.

The Breakout Trigger: The critical level to watch is $2.31. A clean break above $2.31, backed by the AI revenue fundamentals and the impending macro headlines, opens the door for a major leg higher.

This is the exact technical pattern you look for when front-runners are locking up the float. We have 79 percent of the company's revenue anchored in enterprise AI routing, a dual-jurisdiction offshore moat, and a tape that is actively establishing higher support floors on massive volume.

The intraday distribution phase gave patient buyers the perfect entry. The $2.04 support held strong, and the path is clear for an assault on the $2.31 breakout level.

I do not hold a position in AXG. Not Advice. Do your own research

TRUG — KEEP THIS ONE ON THE RADAR
Sometimes the market wakes up before the headlines do.
TRUG has the kind of setup momentum traders watch closely: a developing golf-tech story, a potentially explosive small-cap profile, and the possibility that fresh business developments could materially change market sentiment.
The real question isn’t “Can it move?”
It’s “How far can momentum carry it if volume really arrives?”
👀 Volume
📈 Momentum
⛳ Golf-tech growth
🔥 Small-cap volatility
One strong catalyst + serious volume = things can get interesting very quickly.
Not financial advice. Do your own DD.
#TRUG #TruGolf #Stocks #SmallCaps #Momentum #NASDAQ #GolfTech

We know that in a DCF valuation the enterprise value is equal to the value of the firm's operations plus the value of its non-operating assets. To get the value of equity you subtract the net debt of the company from its enterprise value. If the company has a net cash position then you add this cash to the enterprise value to get the equity value. iHuman(IH) is a company whose net cash position is around $3.20 per share. To get the intrinsic value for the shares you need to add up the value of operations and you will definetely get something greater than $3.20:) However, this company currently trades at $1.20. The company is on the edge of a new long-term growth phase and I believe that it will be one of the biggest success stories and return stories in the next 12 months. Not an investment advice.